Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| (NASDAQ: EDIT) | Delayed: 2.49 -0.02 (0.8%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.51 | 52 Week High | $43.99 | |||
| Open | $2.47 | 52 Week Low | $12.43 | |||
| Day High | $2.58 | P/E | N/A | |||
| Day Low | $2.45 | EPS | $0.00 | |||
| Volume | 1,065,487 | |||||
